83rd Meeting

Gaithersburg Holiday Inn

2 Montgomery Village Avenue

Gaithersburg, MD 20877


Thursday, July 21, 2005


 8:00 a.m. Welcome, Statement of Conflict of Interest, Announcements


8:10 a.m. Committee Updates


-         Summary of May 2005 Meeting of the DHHS Advisory Committee on Blood Safety and Availability – Jerry Holmberg, Ph.D., Executive Secretary, Advisory Committee on Blood Safety and Availability  (10’)


-         Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia Following Anti-D IGIV Administration for Idiopathic Thrombocytopenic Purpura – Ann Gaines, Ph.D., OBE, FDA (15’)


-         Update on Safety of Albumin – Laurence Landow, M.D., OBRR, FDA (5’)


-         Summary of June 2005 Workshop on Biological Therapeutics for Rare Plasma Protein Disorders – Mark Weinstein, Ph.D., OBRR, FDA (10’)


-         Summary of July 2005 Workshop on Leukoreduction - Alan Williams, Ph.D., OBRR, FDA (10’)


-         Update on West Nile Virus Guidance – Alan Williams, Ph.D., Maria Rios, Ph.D., OBRR, FDA and CDR Matthew Kuehnert, Ph.D, CDC (15’)


 9:30 a.m.  Open Committee Discussion


I.              Management of Donors and Units that Test Positive for Hepatitis B Virus (HBV) DNA by Nucleic Acid Tests (NAT)


A.  Introduction and Background – Robin Biswas, M.D., OBRR, FDA (15’)


B.  HBV Seroconversion Panel Results and HBV NAT Positive/Serology Negative Donors - Larry Pietrelli, Roche Molecular Diagnostics (10’)

C.  Temporal Association of HBV NAT and HBsAg Reactivity in Prospectively Screened Source Plasma Donations and Retrospectively Screened Seroconversion Panels – Richard Smith, Ph.D., National Genetics Institute (10’)

D.  Window Period Detection of HBV with the Procleix Ultrio Assay – Larry Mimms, Ph.D., Gen-Probe (10’)

10:15 a.m. BREAK




11:00 a.m. Open Committee Discussion


  E. FDA Perspective and Questions for the Committee

  F. Committee Discussion and Recommendations


12:00 p.m.  LUNCH


1:00 p.m.


II.         Scientific Basis for Review of Varicella Zoster Immune Globulin


A.  Background – Dorothy Scott, M.D., OBRR, FDA (15’)

B.  VZIG Manufacture, Potency Testing and Current Supply Status – Donna Ambrosino, M.D., MPHBL; Catherine A. Hay, Ph.D, MPHBL (15’)

C.  Severe Varicella Zoster Disease, Correlates of Protection and Post-Exposure Prophylaxis Options – Philip La Russa, M.D., Professor Clinical Pediatrics, Columbia University (45’)

D.  Advisory Committee for Immunization Practices Recommendations for Post-Exposure Prophylaxis of Severe Varicella Infections – Mona Marin, M.D., Medical Epidemiologist, National Immunization Program, Center for Disease Control (15’)




3:00 p.m.  Open Committee Discussion


                  E. FDA Perspective and Questions for the Committee

                  F. Committee Discussion and Recommendations


3:45 p.m.  Break

4:00 p.m.


III.    Dextran 1 Pre-treatment For Safe Use of Dextran 40/70


A.          Introduction and Background – Laurence Landow, M.D., OBRR, FDA (10’)

B.          Prevention of Adverse Reactions to Dextran –

Karl-Gφsta Ljungstrφm M.D., Ph.D., Consultant Vascular Surgeon, Associate Professor of Surgery, Karolinska Institute, Department of Surgery, Danderyd Hospital, Sweden (25’)




5:30 p.m.     Open Committee Discussion


                    C. FDA Perspective and Questions for the Committee

                      D. Committee Discussion and Recommendations


6:30 p.m.           Adjournment